Symptomatic benign thyroid diseases are common, and  multinodular goiter with concomitant iodine deficiency is the most frequent  presentation requiring surgical intervention worldwide. Surgery provides  definitive treatment and is the treatment of choice. All surgical options, most  commonly total or near-total thyroidectomy, are used to rule out malignancy in  a benign-appearing thyroid. However, surgery has some inherent risks, including  recurrent hypocalcemia, voice dysfunction, and recurrent laryngeal nerve injury.
    Voice dysfunction and hypocalcemia are the most common  complications after thyroidectomy. It may result from direct or indirect injury  to the recurrent laryngeal nerve leading to transient or permanent vocal cord  paralysis. Indirect nerve injury is reported to be more common than direct  nerve injury. It is postulated that after total thyroidectomy, the strap muscles  exclusively bear the laryngotracheal unit and are the basis of voice  dysfunction. Symptomatic hypocalcemia is the most frequent complication after  total thyroidectomy and occurs in up to 50% of cases. Hypocalcemia results from  loss of the parathyroid glands, and patients with this condition require  supplements such as calcium or vitamin D3 (cholecalciferol) to recover function.
    Various methods have been evaluated to prevent these  complications. The use of steroids (ie, dexamethasone) in the perioperative  period has been shown to improve voice function postoperatively. Intraoperative  neural monitors have also been used to prevent this complication.
    Authors Adeel Dhahri  et al hypothesized that the use of a single preoperative injection of  dexamethasone could reduce postoperative voice dysfunction and hypocalcemia.  They conducted a double-blind controlled trial to assess the effect of  preoperative dexamethasone on vocal dysfunction and hypocalcemia after  thyroidectomy.
    This double-blind, parallel-group, placebo-controlled  randomized clinical trial was conducted from January 15, 2014, to December 31,  2019, at the Department of Surgery, Holy Family Hospital in Rawalpindi,  Pakistan. All patients with a benign thyroid condition and no preoperative  corrected hypocalcemia and voice or vocal quality dysfunction were included.  Patients were excluded if they had previous thyroid or neck surgery, known  vocal cord dysfunction on laryngoscopy, hearing or voice problems, a history of  gastroesophageal reflux, stomach ulcer disease, or contraindications to steroid  use.
    Corrected serum calcium levels and Voice Analog Score were defined  and measured preoperatively. The dexamethasone group received a 2-mL  intravenous dose of 8 mg of dexamethasone 60 minutes before the induction of  anesthesia. In contrast, the placebo group received 2 mL of intravenous normal  saline (0.9%) 60 minutes before the induction of anesthesia. Main outcome  included Evidence of hypocalcemia and voice dysfunction. Voice dysfunction was  defined as a subjective score of less than 50 on a Voice Analog Score scale of  0 to 100 points.
    - A total of 192 patients (mean [SD] age, 38.9 [12.4] years;  156 women [81.2%]) were included in the study, with 96 patients randomized to  each study group (dexamethasone group; placebo group). 
 
    - In the first 24 hours after undergoing thyroidectomy, 47  patients (24.4%) developed hypocalcemia and 18 (9.4%) were symptomatic. 
 
    - At 3 days postthyroidectomy, 4 of 96 patients (4.2%) in the  placebo group had hypocalcemia compared with no patients in the dexamethasone  group. 
 
    - At 24 hours postthyroidectomy, 8 of 96 patients (8.3%) in  the dexamethasone group had voice dysfunction compared with 32 of 96 patients  (33.3%) in the placebo group. 
 
    - A total of 40 patients (20.8%) reported voice dysfunction.  The absolute reduction in the rate of hypocalcemia at 24 hours was 24% (95% CI,  11.9%-35.2%) and at 3 days was 4.2% (–0.44% to 10.0%). 
 
    - The rate of symptomatic hypocalcemia was 19% lower in the  dexamethasone group than in the placebo group (95% CI, 11.1%-27.7%). 
 
    - The rate of voice dysfunction was 25% lower in the  dexamethasone group than in the placebo group (95% CI, 13.7%-35.7%).
 
    In this RCT, patients who received dexamethasone before  thyroidectomy had a lower rate of hypocalcemia in the first 24 hours after  surgery than those who received a placebo. Additionally, only 4  patients (2.1%) had hypocalcemia on the third day after surgery. This study  also confirmed the efficacy of intraoperative dexamethasone for avoiding vocal  nerve palsy, with a significantly lower voice dysfunction rate seen during the  first 24 hours after surgery. Thus, a single preoperative 8-mg dose of  dexamethasone was safe and effective in reducing transient postoperative  hypocalcemia and ameliorating postthyroidectomy voice dysfunction.
    Total thyroidectomy is considered a safe surgical procedure  for benign thyroid diseases, such as Graves disease ormultinodular goiter, with  only a slight risk of complications. Temporary hypocalcemia and  postthyroidectomy voice dysfunction are 2 of the few frequently encountered complications.  Dexamethasone is a corticosteroid and has a well-established immune-modulating  effect at the surgical site; it reduces inflammation, edema, and physiological  stress.
    This RCT demonstrated that a single 8-mg dose of  dexamethasone during the preoperative period was safe and effective in  improving transient, immediate postoperative hypocalcemia as well as temporary  voice dysfunction in patients undergoing thyroidectomy.
    Source: doi:10.1001/jamaoto.2021.2190
 
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.